Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

A Phase III, Randomized, Two-armed, Double-blind, Parallel, Active Controlled Clinical Trial to Determine the Non-inferior Efficacy and Safety of CinnoRA® (Adalimumab, CinnaGen Co.) Versus Humira® for Treatment of Active RA

NCT03172325 is registered in ClinicalTrials.gov with Cinnagen as lead sponsor.

NCT NCT03172325
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT03172325 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
A Phase III, Randomized, Two-armed, Double-blind, Parallel, Active Controlled Clinical Trial to Determine the Non-inferior Efficacy and Safety of CinnoRA® (Adalimumab, CinnaGen Co.) Versus Humira® for Treatment of Active RA
Lead sponsor
Cinnagen
Phase
Phase 3
Overall status
Completed
Start date
November 18, 2015
Completion date
January 4, 2017
Enrollment
136 (actual)
Sites
10

Conditions

As the registry lists them; a condition with its own page is linked.

active rheumatoid arthritis